(3S*,4S*)-1,4-dibenzyl-pyrrolidine-3-carboxylic acid | 895239-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3S*,4S*)-1,4-dibenzyl-pyrrolidine-3-carboxylic acid
• 英文别名: (3R*,4R*)-1,4-dibenzyl-pyrrolidine-3-carboxylic acid；1,4-Bis(phenylmethyl)-trans-3-pyrrolidinecarboxylic acid；(3S,4S)-1,4-dibenzylpyrrolidine-3-carboxylic acid
• CAS: 895239-61-9
• 化学式: C₁₉H₂₁NO₂
• 分子量: 295.381
• InChiKey: VGJHMAVFQJLHKA-QZTJIDSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3S*,4S*)-1,4-dibenzyl-pyrrolidine-3-carboxylic acid 在 palladium(II) hydroxide/carbon sodium hypochlorite 、 2,2,6,6-四甲基哌啶氧化物 、 dimethyl sulfide borane 、 氢气 、 potassium hydrogencarbonate 、 potassium bromide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙酸乙酯 、 甲苯 为溶剂， 反应 10.0h， 生成 (3SR,4SR)-3-benzyl-4-formyl-pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2007/140980

  摘要：

  公开号：
• 作为产物：
  描述：

  (3S*,4S*)-1,4-dibenzyl-pyrrolidine-3-carboxylic acid ammonium salt 以 乙醇 为溶剂， 生成 (3S*,4S*)-1,4-dibenzyl-pyrrolidine-3-carboxylic acid
  参考文献：
  名称：

  WO2006/66896

  摘要：

  公开号：

文献信息

• AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN
  申请人：ESTEVE PHARMACEUTICALS, S.A.

  公开号：EP3858439A1

  公开（公告）日：2021-08-04

  The present invention relates to new compounds that show pharmacological activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the µ-opiod receptor (MOR or mu-opioid). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

  本发明涉及对电压门控钙通道（VGCC）的亚单位α2δ，特别是对电压门控钙通道的α2δ-1亚单位或对电压门控钙通道（VGCC）的亚单位α2δ以及µ-阿片受体（MOR或μ-阿片）显示药理活性的新化合物。该发明还涉及所述化合物的制备方法，以及包含它们的组合物，以及它们作为药物的用途。
• PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS
  申请人：Rogel Olivier

  公开号：US20090247577A1

  公开（公告）日：2009-10-01

  Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (disorder) that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound. The substituted pyrrolidine compounds are especially of the formula I, wherein the substituents are as defined in the specification.

  小说3-单取代、3,4-双取代和3,4,4-三取代吡咯烷化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于β-分泌酶活性和/或β-淀粉样蛋白生成及其后续寡聚体和纤维聚集的疾病（紊乱）；该类化合物的使用用于制备用于治疗依赖于β-分泌酶活性和/或β-淀粉样蛋白生成及其后续寡聚体和纤维聚集的疾病的药物配方；包括所述取代的吡咯烷化合物的药物配方和/或包括给予该取代的吡咯烷化合物的治疗方法。所述取代的吡咯烷化合物特别是公式I的，其中取代基如规范中所定义。
• β-Analogs of PLG (l-prolyl-l-leucyl-glycinamide): Ex-chiral pool syntheses and dopamine D2 receptor modulating effects
  作者：Christoph Thomas、Ursula Ohnmacht、Martin Niger、Peter Gmeiner

  DOI：10.1016/s0960-894x(98)00507-1

  日期：1998.10

  Starting from (S)- and (R)-aspartic acid enantiomerically pure P-proline derivatives were synthesized. These chiral building blocks were transformed into P-analogs of the dopamine receptor modulating peptide PLG. According to dopamine receptor binding studies, significant enhancement of [H-3]pramipexole binding was observed for the isomeres 1a,b and 2a-c. The derivative Ib revealed an activity comparable to PLG. (C) 1998 Elsevier Science Ltd. Air rights reserved.
• [EN] PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS<br/>[FR] DÉRIVÉS DE LA PYRROLIDINE UTILISABLES EN TANT QU'INHIBITEURS DE BACE
  申请人：NOVARTIS AG

  公开号：WO2007140980A1

  公开（公告）日：2007-12-13

  [EN] Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class in the treatment of a disease that depends on the activity of beta- secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound. The substituted pyrrolidine compounds are especially of the formula (I), wherein the substituents are as defined in the specification.
  [FR] La présente invention concerne des nouveaux composés de pyrrolidine porteurs de 3-mono-, 3,4-di- ou 3,4,4-tri-substitutions, lesdits composés étant utilisables pour le diagnostic et le traitement thérapeutique d'un animal homéotherme, en particulier pour le traitement d'une maladie (= affection) qui dépend de l'activité de la bêta-secrétase et/ou de la génération de bêta-amyloïde et l'agrégation subséquente en oligomères et en fibrilles. L'invention concerne également l'utilisation d'un composé de cette classe pour la préparation d'une formulation pharmaceutique destinée au traitement d'une maladie qui dépend de l'activité de la bêta-secrétase et/ou de la génération de bêta-amyloïde et l'agrégation subséquente en oligomères et en fibrilles ; l'utilisation d'un composé de cette classe pour le traitement d'une maladie qui dépend de l'activité de la bêta-secrétase et/ou de la génération de bêta-amyloïde et l'agrégation subséquente en oligomères et en fibrilles ; des formulations pharmaceutiques comprenant un desdits composés de pyrrolidine porteurs de substitutions et/ou un procédé de traitement comprenant l'administration d'un desdits composés de pyrrolidine porteurs de substitutions. Les composés de pyrrolidine porteurs de substitutions répondent en particulier à la formule (I), dans laquelle les substituants sont tels que définis dans la spécification.
• WO2006/66896
  申请人：——

  公开号：——

  公开（公告）日：——